Agency Information Collection Activities; Announcement of Office of Management and Budget Approval; Guidance for Industry on Special Protocol Assessment, 24729 [2014-09913]
Download as PDF
Federal Register / Vol. 79, No. 84 / Thursday, May 1, 2014 / Notices
Remaining Operating Rules; and (3) A letter
emphasizing NCVHS’s long-standing position
on the adoption of ICD–10 code sets in the
US.
Contact Person for More Information:
Debbie Jackson, Interim Executive Secretary,
NCVHS, National Center for Health Statistics,
Centers for Disease Control and Prevention,
3311 Toledo Road, Room 2402, Hyattsville,
Maryland 20782, telephone (301) 458–4614;
Written comments should be sent directly to
Terri Deutsch, lead staff for the Standards
Subcommittee, NCVHS, Centers for Medicare
and Medicaid Services, Office of E-Health
Standards and Services, 7500 Security
Boulevard, Mailstop S2–26–17, Baltimore,
Maryland 21244, email Terri.Deutsch@
cms.hhs.gov, phone (410) 786–9462.
Program information as well as summaries
of meetings and a roster of committee
members are available on the NCVHS home
page of the HHS Web site: https://
www.ncvhs.hhs.gov/, where further
information including an agenda will be
posted when available.
Dated: April 23, 2014.
James Scanlon,
Deputy Assistant Secretary for Planning and
Evaluation, Office of the Assistant Secretary
for Planning and, Evaluation.
[FR Doc. 2014–09903 Filed 4–30–14; 8:45 am]
Biologics’’ to OMB for review and
clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor,
and a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0765. The
approval expires on March 31, 2017. A
copy of the supporting statement for this
information collection is available on
the Internet at https://www.reginfo.gov/
public/do/PRAMain.
Dated: April 25, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–09914 Filed 4–30–14; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–1394]
Food and Drug Administration,
HHS.
[Docket No. FDA–2013–D–0575]
ACTION:
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Guidance for Industry on Expedited
Programs for Serious Conditions—
Drugs and Biologics
SUMMARY:
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Guidance for Industry on Expedited
Programs for Serious Conditions—Drugs
and Biologics’’ has been approved by
the Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 1350 Piccard
Dr., PI50–400B, Rockville, MD 20850,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On
December 31, 2013, the Agency
submitted a proposed collection of
information entitled ‘‘Guidance for
Industry on Expedited Programs for
Serious Conditions—Drugs and
tkelley on DSK3SPTVN1PROD with NOTICES
SUMMARY:
VerDate Mar<15>2010
17:30 Apr 30, 2014
Jkt 232001
Dated: April 25, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014–09913 Filed 4–30–14; 8:45 am]
BILLING CODE 4160–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2013–N–0338]
Center for Devices and Radiological
Health: Experiential Learning Program
AGENCY:
ACTION:
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
AGENCY:
Food and Drug Administration
the Internet at https://www.reginfo.gov/
public/do/PRAMain.
Notice.
The Food and Drug
Administration (FDA) is announcing
that a collection of information entitled
‘‘Guidance for Industry on Special
Protocol Assessment’’ has been
approved by the Office of Management
and Budget (OMB) under the Paperwork
Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT: FDA
PRA Staff, Office of Operations, Food
and Drug Administration, 1350 Piccard
Dr., PI50–400B, Rockville, MD 20850,
PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On
February 19, 2014, the Agency
submitted a proposed collection of
information entitled ‘‘Guidance for
Industry on Special Protocol
Assessment’’ to OMB for review and
clearance under 44 U.S.C. 3507. An
Agency may not conduct or sponsor,
and a person is not required to respond
to, a collection of information unless it
displays a currently valid OMB control
number. OMB has now approved the
information collection and has assigned
OMB control number 0910–0470. The
approval expires on March 31, 2017. A
copy of the supporting statement for this
information collection is available on
PO 00000
Frm 00063
Fmt 4703
Food and Drug Administration,
HHS.
Agency Information Collection
Activities; Announcement of Office of
Management and Budget Approval;
Guidance for Industry on Special
Protocol Assessment
BILLING CODE 4151–05–P
24729
Sfmt 4703
Notice.
The Food and Drug
Administration (FDA) Center for
Devices and Radiological Health (CDRH
or Center) is announcing an invitation
for participation in its Experiential
Learning Program (ELP). The ELP
provides a formal training mechanism
for regulatory review staff to visit
research, clinical, manufacturing, and
health care facilities to observe firsthand
how medical devices are designed,
developed, and utilized. This training is
intended to provide CDRH staff with an
opportunity to observe the device
development life cycle and provide a
better understanding of the medical
devices they review and the challenges
faced throughout development, testing,
manufacturing, and clinical use. The
purpose of this document is to invite
medical device industry, academia, and
health care facilities to participate in
this formal training program for FDA’s
medical device review staff, or to
contact CDRH for more information
regarding the program.
DATES: Submit either an electronic or
written request for participation in this
program by June 2, 2014. The request
should include a description of your
facility relative to product areas
regulated by CDRH. Please include the
Area of Interest (see table 1 or 2) that the
site visit will demonstrate to CDRH
staff, a contact person, site visit
location, length of site visit, proposed
dates, and maximum number of CDRH
staff that can be accommodated during
a site visit. Submitted proposals without
this information will not be considered.
In addition, please include an agenda
outlining the proposed training for the
site visit. A sample request and agenda
are available on the ELP Web site:
https://www.fda.gov/downloads/
ScienceResearch/
SUMMARY:
E:\FR\FM\01MYN1.SGM
01MYN1
Agencies
[Federal Register Volume 79, Number 84 (Thursday, May 1, 2014)]
[Notices]
[Page 24729]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-09913]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2013-N-1394]
Agency Information Collection Activities; Announcement of Office
of Management and Budget Approval; Guidance for Industry on Special
Protocol Assessment
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing that a
collection of information entitled ``Guidance for Industry on Special
Protocol Assessment'' has been approved by the Office of Management and
Budget (OMB) under the Paperwork Reduction Act of 1995.
FOR FURTHER INFORMATION CONTACT: FDA PRA Staff, Office of Operations,
Food and Drug Administration, 1350 Piccard Dr., PI50-400B, Rockville,
MD 20850, PRAStaff@fda.hhs.gov.
SUPPLEMENTARY INFORMATION: On February 19, 2014, the Agency submitted a
proposed collection of information entitled ``Guidance for Industry on
Special Protocol Assessment'' to OMB for review and clearance under 44
U.S.C. 3507. An Agency may not conduct or sponsor, and a person is not
required to respond to, a collection of information unless it displays
a currently valid OMB control number. OMB has now approved the
information collection and has assigned OMB control number 0910-0470.
The approval expires on March 31, 2017. A copy of the supporting
statement for this information collection is available on the Internet
at https://www.reginfo.gov/public/do/PRAMain.
Dated: April 25, 2014.
Leslie Kux,
Assistant Commissioner for Policy.
[FR Doc. 2014-09913 Filed 4-30-14; 8:45 am]
BILLING CODE 4160-01-P